Page 2 - Bioworld Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bioworld science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bioworld Science Today - Breaking & Trending Today

Xaira launches with $1B+ for AI drug development

In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023. ....

Galderma Inc , Roivant Sciences Inc , Xaira Therapeutics , Roivant Sciences , Machine Learning , Bioworld Science , Drug Design , Rug Delivery And Technologies , Artificial Intelligence , Newco News , Small Molecule ,

Peripartum cardiomyopathy is associated with placental senescence

Scientists at Massachusetts General Hospital have linked the risk of heart failure during pregnancy and senescence proteins produced by placental aging, which could clarify how peripartum cardiomyopathy (PPCM) is triggered and opens the door to the development of cardiac function therapies in late pregnancy. ....

United States , Massachusetts General Hospital , Bioworld Science , Peripartum Cardiomyopathy , Heart Failure , Neonatal Pediatrics ,

Broader KRAS inhibition methods include chaperoning, gluing, vaccinating

The existence of two approved therapies, Lumakras (sotorasib, Amgen Inc.) and Karzati (adagrasib, Mirati Therapeutics Inc.), has been a triumphant success against KRAS, a protein that was once considered undruggable. KRAS is the most frequently mutated oncogene in solid tumors. KRAS driver mutations are found in about 30% of non-small-cell lung cancers (NSCLC), about half of colorectal cancers, and more than 90% of pancreatic cancers. Lumakras and Karzati both target the G12C mutation. Inhibitors that target other mutations, like G12D, are now making their way through preclinical and clinical development, while some companies are developing therapies that would target mutated KRAS more broadly, irrespective of the specific mutation that is activating the protein. ....

Mirati Therapeutics Inc , Amgen Inc , Bioworld Science , Revolution Medicines Inc , Pancreatic Cancer , Non Small Cell Lung Cancer , Elicio Therapeutics Inc , Quanta Therapeutics Inc , Molecular Glues , Colon Cancer , Rmc 6236 , Nested Therapeutics Inc , Eli 002 , Tri Complex Inhibitors , Qtx 3544 , Nst 628 , American Association For Cancer Research ,

Outrun emerges from stealth with $10M for E3 ligase inhibitors

Newco Outrun Therapeutics Ltd. has raised $10 million in a seed round to develop small-molecule E3 ubiquitin ligase inhibitors that prevent programmed protein degradation. The lead program targeting an E3 ligase that tags a tumor suppressor protein for destruction will now advance to preclinical development. ....

Newco Outrun Therapeutics Ltd , Newco Outrun Therapeutics , Protein Degradation , E3 Ligase Inhibitors , Outrun Therapeutics Ltd , Protein Stabilization , Bioworld Science , Newco News , Small Molecule ,

Interstitial macrophages trigger severe COVID in the lung

SARS-CoV-2 could proliferate in the lungs causing severe COVID-19 through a special type of immune cell. A group of scientists from Stanford University observed how this coronavirus infected interstitial macrophages through a CD209 receptor, triggering the inflammatory response observed in hospitalized patients. ....

Stanford University , Bioworld Science , Covid 19 , Sars Cov 2 , University Of California , San Francisco , Severe Covid , Stanford University School Of Medicine ,